The stock of Akebia Therapeutics Inc. (NASDAQ:AKBA) last traded at $1.63, down -10.93% from the previous session.
AKBA stock price is now 0.37% away from the 50-day moving average and 27.21% away from the 200-day moving average. The market capitalization of the company currently stands at $341.27M.
On August 28, 2023, H.C. Wainwright Upgraded its previous ‘Neutral’ rating to ‘Buy’ on the stock keeping its target price maintained at $3.75, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Butler John P., CEO and President sold 46,570 shares of the company’s stock on Feb 29 ’24. The stock was sold for $73,581 at an average price of $1.58. Upon completion of the transaction, the CEO and President now directly owns 2,044,580 shares in the company, valued at $3.33 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 29 ’24, SVP, Chief Operating Officer Dahan Michel sold 8,661 shares of the business’s stock. A total of $13,684 was realized by selling the stock at an average price of $1.58. This leaves the insider owning 706,932 shares of the company worth $1.15 million. A total of 12.05% of the company’s stock is owned by insiders.
During the past 12 months, Akebia Therapeutics Inc. has had a low of $0.49 and a high of $2.48. The fifty day moving average price for AKBA is $1.6384 and a two-hundred day moving average price translates $1.2926 for the stock.
The latest earnings results from Akebia Therapeutics Inc. (NASDAQ: AKBA) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0, beating analysts’ expectations of -$0.04 by 0.04. This compares to -$0.03 EPS in the same period last year. The net profit margin was -26.32% and return on equity was -554.87% for AKBA. The company reported revenue of $56.07 million for the quarter, compared to $55.71 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.66 percent. For the current quarter, analysts expect AKBA to generate $46.34M in revenue.
Akebia Therapeutics Inc.(AKBA) Company Profile
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
